Daiichi Sankyō

Update in progress

4568.T (Tokyo)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - General

Daiichi Sankyo Company, Limited develops and sells medicines worldwide. Key products include Enhertu for HER2-positive cancers; Turalio and Vanflyta; Injectafer, Venofer; DATROWAY; Liziana and Savaysa; Olmetec/Olmetec Plus/Sevikar; Nilemdo and Nustendi; Efient; Canalia and Tenelia; Emgalty and Reyvow; Pralia; Ranmark; Tarlige; Vimpat; and vaccines for COVID-19 and influenza. It collaborates with Lunit for biomarker research. Founded 1899, based in Tokyo.

Company score

Sentiment: -0.18; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.05; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.13; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.04; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.11; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive